User:Amélie C. Martin/sandbox
From Wikipedia, the free encyclopedia
MOR103 (also known as GSK3196165) is a so-called fully human antibody which has been developed by the biotechnology company MorphoSys[3]. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. MOR103 is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.
More information Clinical data ...
Clinical data | |
---|---|
Used names | MOR103, GSK3196165 |
License | Formerly MorphoSys |
Outlicensed to GlaxoSmithKline (GSK) in 2013 | |
Legal status | Phase 2 clinical trial (RA) |
Phase 1b clinical trial (MS) |
Close